September 5, 2024 11:11 AM EDT
News Briefing

No­var­tis pays $15M up­front to li­cense Voy­ager pro­gram; Boehringer ad­vances ge­o­graph­ic at­ro­phy drug

ENDPOINTS

Plus, news about Jnana Ther­a­peu­tics, Vax­cyte, C-Fur­ther, Gen­prex, Phar­maEssen­tia, FORUS Ther­a­peu­tics, Phar­ma Two B and He­p­i­on:

No­var­tis li­cens­es Voy­ager pro­gram: Voy­ager will get $15 mil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Viking CEO on ‘shock­ing’ mar­ket re­ac­tion to oral obe­si­ty da­ta, prepar­ing for Phase 3

Sana nar­rows fo­cus again to ze­ro in on di­a­betes and au­toim­mune dis­ease

Ver­tex makes mon­ey from sick­le cell ther­a­py Cas­gevy

The elec­tion is Tues­day. What’s at stake for the phar­ma in­dus­try?

'We play to win': As­traZeneca de­tails first re­sults for oral GLP-1 and broad­er obe­si­ty am­bi­tions

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times